The Joint Program Executive Office for Chemical and Biological Defense is seeking information on the capabilities of organizations to develop or manufacture a diazepam autoinjector with an anticonvulsant indication against organophosphate poisoning. [Read more]
An innovative approach is being initiated by the Department of Defense, which will accelerate MCM delivery by leveraging platform technologies that can be applied to a broad range of threats, and that [Read more]
Therapeutic pharmaceuticals against chemical, biological, radiological and nuclear (CBRN) warfare agents are required to support the Joint Forces across a range of military operations. As such, the U.S. Department of Defense (DoD) [Read more]
No definitive diagnostic test exists for Burkholderia, a category B agent caused by Burkholderia pseudomallei bacterium, which poses a threat to deployed servicemembers. The Defense Threat Reduction Agency’s Chemical and Biological Technologies [Read more]
The Enhanced Maritime Biological Detection (EMBD) program is charged with finalizing development, and complete testing, integration and production of an automated biological warfare agent point detection system. The EMBD program has issued [Read more]
The Defense Biological Product Assurance Office (DBPAO), previously known as the Critical Reagents Program (CRP), is conducting market research on capabilities of commercial partners to provide reagent services for select biological threat agents. [Read more]
The U.S. Department of Defense has recently awarded a notable contract related to the field of chemical, biological, radiological and nuclear (CBRN) equipment or life science research of interest for potential applications [Read more]
The U.S. Department of Defense (DoD) is conducting market research to identify vaccine developers who have advanced manufacturing platforms which are adaptable to incorporating known antigens for use as a prophylaxis countermeasure [Read more]
The U.S. Department of Defense is seeking information from organizations on their capability to support advanced development of human butyrylcholinesterase (HuBChE) as a medical countermeasure. Overseen by the Joint Product Manager – [Read more]
Battelle was recently selected as a qualifying contractor to bid for chemical and biological defense work for the next five years under the $900 million Joint Enterprise Contracted Logistics and Services Support [Read more]
© 2019 STEMAR MEDIA